SCHEMBL7685599

SCHEMBL7685599

CC(C)(C)C(NC(=O)O)c1cccs1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.41
CES2 O00748 1/20 0.40
CES1 P23141 1/20 0.40
KEAP1 Q14145 1/20 0.40
MAPT P10636 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
GAA P10253 2/20 0.38
HSD17B10 Q99714 1/20 0.38
TSHR P16473 2/20 0.38
ALDH1A1 P00352 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
GFER P55789 1/20 0.38
POLB P06746 3/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
APEX1 P27695 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27826689 0.77 ALDH1A1 (0.52) ALOX5CES2CES1KEAP1MAPT
SCHEMBL4080372 0.77 CES2 (0.46) ALOX5CES2CES1KEAP1MAPT
SCHEMBL10452109 0.74 CES2 (0.43) ALOX5CES2CES1KEAP1MAPT
SCHEMBL1164188 0.72 DAO (0.38) CES2CES1MAPTMEN1KMT2A
SCHEMBL72374 0.70 CES2 (0.50) ALOX5CES2CES1KEAP1MAPT
SCHEMBL19319084 0.70 ALDH1A1 (0.49) ALOX5CES2CES1KEAP1MAPT
SCHEMBL10452064 0.70 CES2 (0.40) ALOX5CES2CES1KEAP1MAPT
SCHEMBL19319112 0.70 ALDH1A1 (0.49) ALOX5CES2CES1KEAP1MAPT
SCHEMBL27978009 0.69 RAB9A (0.45) CES2CES1MAPTMEN1KMT2A
SCHEMBL10316460 0.69 ALOX5 (0.43) ALOX5CES2CES1KEAP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020042428-A1 Quinuclidine-substituted heteroaryl moieties for treatment of disease PHARMACIA & UPJOHN COMPANY 2002-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042428-A1 Quinuclidine-substituted heteroaryl moieties for treatment of disease NQO2, GBA1, UGT1A1 ALOX5 1947/4885CES2 255/4885CES1 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.